Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246310 | 1.00 | KHK (0.57) | KHKADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL15378488 | 1.00 | KHK (0.57) | KHKADRB1HTR3EHTR3BHTR3A | |
| Hydrochloric Acid SCHEMBL15819287 | 0.98 | KHK (0.56) | KHKADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL1005494 | 0.90 | KHK (0.52) | KHKADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL5268403 | 0.90 | KHK (0.52) | KHKADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL15579346 | 0.85 | HTR7 (0.62) | KHKMAPTALDH1A1CYP3A4MAPK1 | |
| SCHEMBL24123867 | 0.83 | ADRB1 (0.58) | KHKADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL28320410 | 0.83 | SIGMAR1 (0.57) | KHKADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL6786862 | 0.83 | ADRB1 (0.58) | KHKADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL2245943 | 0.83 | ADRB1 (0.58) | KHKADRB1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736236-B | Polynuclear annular organotin oxygen sulfur cluster compound and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2023-09-29 | — | — | CN | claimed |
| CN-114736236-A | Polynuclear cyclic organotin-oxygen-sulfur cluster compound and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2022-07-12 | — | — | CN | claimed |
| WO-2024151809-A1 | INHIBITORS OF BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE 2 (BMPR2) AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-07-18 | — | — | WO | disclosed |
| CN-114736236-B | Polynuclear annular organotin oxygen sulfur cluster compound and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2023-09-29 | — | — | CN | disclosed |
| CN-114736236-A | Polynuclear cyclic organotin-oxygen-sulfur cluster compound and preparation method and application thereof | 中国科学院福建物质结构研究所 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022010537-A1 | GAS41 INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-2938608-B1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD BURNHAM MED RES INST (US) | 2021-08-04 | — | — | EP | disclosed |
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3784234-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2014100501-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| CN-101679400-B | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | SK HOLDINGS CO LTD | 2013-04-17 | — | — | CN | disclosed |
| CN-101679400-A | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound | SK HOLDINGS CO LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2060575-A1 | Dihydrothienopyrimidines and their use in treating inflammatory diseases | Boehringer Ingelheim International GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| EP-1830854-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | Schwarz Pharma, s.l. (ES) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006069993-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | SCHWARZ PHARMA S.L. (ES) | 2006-07-06 | — | — | WO | disclosed |
| US-6825200-B1 | TREATING, PROLONGING, OR EXTENDING THE ONSET OF ORGAN REJECTION IN A HUMAN DURING OR AFTER ORGAN TRANSPLANTATION IN A HUMAN | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | HRH2, NPY2R, CNKSR1 | KHK 2539/4885ADRB1 167/4885HTR3E 2553/4885 |
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | KHK 4679/4885ADRB1 61/4885HTR3E 9/4885 |
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KHK 3414/4885ADRB1 4095/4885HTR3E 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.